ProCE Banner Activity

HR-Positive/HER2-Negative Early Breast Cancer Patient Resource: Questions for Your Care Team

PDF

Help your patients plan their treatment for HR-positive/HER2-negative early breast cancer with this downloadable resource on starting endocrine therapy and a CDK4/6 inhibitor.

Released: January 18, 2024

Share

Faculty

Julia LaBarbera

Julia LaBarbera, MSN, RN, AGACNP-BC

  • Nurse Practitioner
    Division of Hematology/Oncology
    Department of Medicine
    University of California, Los Angeles
    Santa Monica, California

Provided by

Provided by Clinical Care Options, LLC, in partnership with Breastcancer.org and Smart Patients Inc.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Julia LaBarbera, MSN, RN, AGACNP-BC

  • Nurse Practitioner
    Division of Hematology/Oncology
    Department of Medicine
    University of California, Los Angeles
    Santa Monica, California

Julia A. LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, I3Health.